You are hereOctober 7, 2021
New hope for the treatment of Fukuyama congenital muscular dystrophy
TOYOAKE (JP), October 2021 — Fukuyama congenital muscular dystrophy (FCMD) is a severe genetic neuromuscular disorder affecting the eyes, brain and muscles. FCMD is caused by mutations disrupting the glycosylation (addition of sugars) of α-dystroglycan (αDG), a protein required for maintaining muscle integrity. During fetal development, the lack of glycosylation destroys αDG function, leading to severe muscular dystrophy, intellectual disabilities, seizures and insomnia. Infants born with FCMD have low life expectancies, and patients typically do not survive into their 20s. Despite this, no cure for FCMD has been discovered yet, partly owing to the unavailability of appropriate animal models for research.
In a recent breakthrough, scientists from Japan and the United States have developed the first human disease model of FCMD using stem cells from a patient with FCMD. Their study, published in iScience, describes the effectiveness of a small compound called Mannan-007 (Mn007) in reducing FCMD-related defects in this model.
For Mariko Taniguchi-Ikeda, M.D., Ph.D., assistant professor at the Fujita Health University Hospital and lead investigator on this study, finding a cure for FCMD has been a life-long mission. She said, “Having worked with patients with FCMD for more than 20 years, I understood the importance of attempting to cure this disease. But first, we needed a better model to study FCMD in the laboratory.”
To solve this problem, Dr. Taniguchi-Ikeda’s team transformed pluripotent stem cells derived from an FCMD patient into skeletal muscle and “brain organoids” — artificially grown miniature organs resembling the brain. “Using a brain organoid model derived from pluripotent stem cells, we showed the restoration of defects in the radial architecture of neurons and cortical plate organization of Fukuyama muscular dystrophy,” explained Takashi Aoi, M.D., Ph.D., from Kobe University, who collaborated with Dr. Taniguchi-Ikeda on this study.
The brain organoids successfully mimicked the features of FCMD, including the low levels of αDG glycosylation. They also showed impairments in neuronal migration — a process crucial for normal brain development — owing to a disorganized arrangement of guiding cells called radial glia. This new fetal human brain model of FCMD was therefore superior to animal models, which do not fully reproduce FCMD-like brain anomalies.
Encouraged by the successful development of this model, the team set out to test potential treatment options for FCMD. In particular, they investigated whether the small compound Mn007 could reduce the FCMD-like defects observed in the organoids. Dr. Taniguchi-Ikeda explained, “Because of gene mutations, the multi-step process of αDG glycosylation is impaired in FCMD. We hypothesized that the addition of a molecule like Mn007 that can promote αDG glycosylation would rescue the defects observed in FCMD.”
To their delight, their hypothesis was validated. They observed that Mn007 could restore the levels of αDG in both the muscle and brain models tested. Further, brain organoids treated with Mn007 showed partial improvements in radial glial architecture and neuronal migration, resulting in fewer development defects. Their findings highlighted the importance of αDG glycosylation in regulating these processes and demonstrated the potential of Mn007 and similar molecules in therapies for FCMD and related diseases.
This study from Dr. Taniguchi-Ikeda and her team brings a ray of hope for thousands of potential parents worldwide, and especially in Asia where most cases of FCMD are encountered.
“Mn007 can cross over from the blood into the brain. Therefore, it could be a viable prenatal option for restoring normal neuronal migration in patients with FCMD and other diseases caused by glycosylation defects in αDG and reducing their brain-related symptoms. This is an exciting opportunity for clinical translation down the road,” commented Bennett G. Novitch, Ph.D., from the David Geffen School of Medicine at the University of California, who also contributed to this study. His co-author, Momoko Watanabe, Ph.D., from the University of California, Irvine, added that their findings also offer a valuable opportunity for delineating the molecular mechanisms that lead to migration defects caused by the lack of αDG glycosylation in FCMD.
Scientists from Japan and the USA developed a reliable brain organoid model for studying FCMD using stem cells from patients with the disease. Subsequently, they showed that treatment with the compound Mannan-007 can reduce the defects associated with FCMD in these organoids, demonstrating its potential for the treatment of this currently incurable disease. Image courtesy of Mariko Taniguchi-Ikeda, Fujita Health University.